Safety outcomes:
Safety analyses included assessment of adverse events and central
laboratory testing; serum potassium and creatinine levels. Adverse
events that occurred during the treatment period were defined as those
that started or worsened during finerenone or placebo intake or up to 3
days after any temporary or permanent interruption.